Gilead's Kevin Young appointed Commander of the British Empire
This article was originally published in Scrip
Executive Summary
Kevin Young, Gilead's executive vice-president of commercial operations, has been appointed a Commander of The British Empire in recognition of his "services to the healthcare and pharmaceutical industries, particularly to the development and marketing of life-changing medicines." The civilian honour comes after 28 years in the biotech and pharmaceutical sector. He joined Gilead in 2004 after working at companies including Amgen and AstraZeneca.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.